<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163881">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964678</url>
  </required_header>
  <id_info>
    <org_study_id>HM12120</org_study_id>
    <nct_id>NCT00964678</nct_id>
  </id_info>
  <brief_title>Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension</brief_title>
  <official_title>Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether carvedilol treatment of patients with
      pulmonary arterial hypertension and associated right heart failure is safe and results in an
      improved function of the right heart.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in right ventricular ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>determined by cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>right ventricular end systolic volume</measure>
    <time_frame>6 months</time_frame>
    <description>determined by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tricuspid annular plane systolic excursion</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>twice daily oral treatment in escalating dose</description>
    <arm_group_label>carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic, familial or associated PAH, WHO group 1

          -  NYHA class II or III

          -  clinically stable with optimized PAH treatment for at least 3 months

          -  no or minimal evidence of fluid overload or volume depletion, with or without
             diuretic treatment

          -  age &gt; 18 years

          -  mean pulmonary artery pressure (mPAP) &gt; 25 mmHg

          -  6 minute walk distance (6MWD) over 100m

        Exclusion Criteria:

          -  Structural heart disease unrelated to PAH

          -  Recent (&lt;3 months) treatment with an intravenous positive inotropic agent

          -  current use of β-blockers

          -  history of reactive airways disease

          -  history of adverse reaction to β-blockers

          -  heart block on ECG or resting heart rate &lt; 60 bpm

          -  cardiac index &lt; 1.8 l/min/m2

          -  systemic hypotension (systolic pressure &lt; 90 mmHg)

          -  pulmonary capillary wedge pressure &gt; 15 mmHg

          -  inability to give informed consent

          -  contraindications to CT and/or PET scanning

          -  coagulopathy (INR&gt;1.5 or platelet count&lt;50000/mm3)

          -  severe renal insufficiency (creatinine clearance &lt;30 ml/min/m2)

          -  malignancy or any co-morbidity limiting survival or conditions predicting inability
             to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C Grinnan, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel C Grinnan, MD</last_name>
      <phone>804-519-8705</phone>
      <email>dcgrinnan@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel C Grinnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 11, 2013</lastchanged_date>
  <firstreceived_date>August 24, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
